BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31342381)

  • 1. Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB?
    Imeokparia FO; Hughes TM; Dossett LA; Jeruss JS; Chang AE; Sabel MS
    Ann Surg Oncol; 2019 Oct; 26(10):3374-3379. PubMed ID: 31342381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.
    DeSnyder SM; Mittendorf EA; Le-Petross C; Krishnamurthy S; Whitman GJ; Ueno NT; Woodward WA; Kuerer HM; Akay CL; Babiera GV; Yang W; Lucci A
    Clin Breast Cancer; 2018 Feb; 18(1):e73-e77. PubMed ID: 28755879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
    Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
    Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Breast Cancer Pretreatment Nodal Burden and Disease Subtype on Axillary Surgical Management.
    Ng S; Sabel MS; Hughes TM; Chang AE; Dossett LA; Jeruss JS
    J Surg Res; 2021 May; 261():67-73. PubMed ID: 33421795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization.
    Sun J; Henry DA; Carr MJ; Yazdankhahkenary A; Laronga C; Lee MC; Hoover SJ; Sun W; Czerniecki BJ; Khakpour N; Kiluk JV
    Clin Breast Cancer; 2021 Jun; 21(3):e189-e193. PubMed ID: 32893094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?
    Baker JL; Muhsen S; Zabor EC; Stempel M; Gemignani ML
    Ann Surg Oncol; 2019 Feb; 26(2):336-342. PubMed ID: 30506175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment.
    Roos MM; van Steenhoven JEC; Aalders KC; Schreuder K; Burgmans JPJ; Siesling S; Elias S; van Dalen T
    Ann Surg Oncol; 2019 Feb; 26(2):372-378. PubMed ID: 30387028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment.
    Siso C; de Torres J; Esgueva-Colmenarejo A; Espinosa-Bravo M; Rus N; Cordoba O; Rodriguez R; Peg V; Rubio IT
    Ann Surg Oncol; 2018 Mar; 25(3):784-791. PubMed ID: 29197044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
    Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
    Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
    Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Axillary Evaluation Using Reflector-Guided Sentinel Lymph Node Biopsy: A Prospective Feasibility Study and Comparison With Conventional Lymphatic Mapping Techniques.
    Taback B; Jadeja P; Ha R
    Clin Breast Cancer; 2018 Oct; 18(5):e869-e874. PubMed ID: 29544701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.